|
|
|
|
|
|
|
|
|||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | |||||
|
Fig. 4. In HeLa cells endogenous SNX2 and SNX1 co-localise on an early endosomal compartment. (A) HeLa cells were treated with control, SNX2-specific, SNX1-specific or both SNX2 and SNX1 siRNA duplexes for 72 hours. At this time, the levels of SNX2 and SNX1 were determined by western blotting with SNX2 or SNX1 antisera. In all cases loading was controlled by probing samples with an anti-tubulin antibody. Quantification of the data revealed that, for individual siRNA treatment using SNX2-specific or SNX1-specific duplexes, the level of SNX2 and SNX1 expression was suppressed by 82% and 93%, respectively. Under conditions of simultaneous duplex treatment, SNX2 and SNX1 were suppressed by 81% and 92%, respectively. (B) HeLa cells were treated with control, SNX2-specific, SNX1-specific or both SNX2 and SNX1 siRNA duplexes for 72 hours prior to fixation. Cells were stained for endogenous SNX1 and SNX2. Bar, 10 µm. (C) HeLa cells were fixed and co-stained with SNX1- and SNX2-specific antibodies to reveal the endogenous distribution of these proteins. Bar, 10 µm.
|
